Keyphrases
Breast Cancer Patients
100%
Estrogen
100%
Good Prognosis
100%
Estrogen Receptor Status
100%
Adjuvant Endocrine Therapy
100%
Activity Profile
71%
Disease-free Survival
57%
B-cell Lymphoma 2 (Bcl-2)
57%
Progesterone Receptor
57%
Insulin-like Growth Factor 1 Receptor (IGF1R)
57%
Overall Survival
42%
Estrogen Receptor
42%
Human Epidermal Growth Factor Receptor 2 (HER2)
42%
Estrogen Receptor-positive
28%
Letrozole
28%
Breast Cancer Risk
14%
Multivariate Analysis
14%
Tumor
14%
Univariate Analysis
14%
Insulin-like
14%
Tumor Growth
14%
Tumor Tissue
14%
High-level Expression
14%
Immunohistochemical Staining
14%
Adjuvant Chemotherapy
14%
Receptor 2
14%
Improved Survival
14%
Estrogen Receptor-positive Breast Cancer
14%
Cell Growth
14%
Activity Groups
14%
Group-based
14%
Patient Analysis
14%
Tumor Levels
14%
Phase III Clinical Trial
14%
Further Analysis
14%
Growth Hormone Receptor
14%
BIG 1-98
14%
HercepTest
14%
Medicine and Dentistry
Breast Cancer
100%
Estrogen Receptor
100%
Adjuvant Endocrine Therapy
100%
Disease Free Survival
33%
Progesterone Receptor
33%
Neoplasm
25%
Overall Survival
25%
Tamoxifen
16%
Letrozole
16%
Multivariate Analysis
8%
Clinical Trial
8%
Univariate Analysis
8%
Tumor Progression
8%
Cell Growth
8%
Adjuvant Chemotherapy
8%
Estrogen Receptor Positive Breast Cancer
8%
Somatomedin C Receptor
8%
Pharmacology, Toxicology and Pharmaceutical Science
Endocrine Therapy
100%
Breast Cancer
100%
Estrogen Receptor
100%
Disease Free Survival
33%
Progesterone Receptor
33%
Neoplasm
25%
Overall Survival
25%
Tamoxifen
16%
Letrozole
16%
Clinical Trial
8%
Chemotherapy
8%
Tumor Growth
8%
Estrogen Receptor Positive Breast Cancer
8%
Somatomedin C Receptor
8%
Biochemistry, Genetics and Molecular Biology
Estrogen Receptor
100%
Disease Free Survival
30%
Progesterone Receptor
30%
Bcl-2
30%
Overall Survival
23%
Letrozole
15%
Tumor Progression
7%
Clinical Trial
7%
Cell Growth
7%
Multivariate Analysis
7%
Insulin-Like Growth Factor 1 Receptor
7%